Add BrightSurf on Google Email

Two-pronged attack strategy boosts immunotherapy in preclinical studies

A new immunotherapy approach employs a two-pronged attack against solid tumors to boost the immune system's ability to target and eliminate cancer cells. By combining CV1-producing T cells with cancer-targeting antibodies, researchers improved macrophage consumption of tumor cells, suggesting a potential solution to treatment challenges.

SourceLudwig Institute for Cancer Research·JournalJournal of Clinical Investigation·DateJun 3, 2024

Fred Hutch at ASCO: Progress in treating metastatic cancer, hospice access for cancer patients, use of machine learning with CAR T-cell therapy

Fred Hutch researchers present progress in treating metastatic cancer with novel therapies, including a Phase II study testing TNF-a inhibitors for castration-resistant prostate cancer. The center also explores improving hospice access and using machine learning with CAR T-cell therapy to enhance patient outcomes.

An immunotherapy to overcome resistant leukemia

Researchers have discovered a new immunotherapy approach to overcome resistant leukemia by targeting the mutated TP53 gene. Combining pharmacological therapies with genetically engineered CAR T-cells increases effectiveness against cancer cells, offering promising strategies for patients with resistant disease.

SourceUniversity of Zurich·JournalEMBO Molecular Medicine·TypeExperimental study·DateMar 21, 2024

DNA origami-based vaccines toward safe and highly-effective precision cancer immunotherapy

A new DNA origami platform, DoriVac, enables precise spacing of adjuvant molecules and a variety of antigens to enhance anti-tumor responses. The vaccine demonstrated enhanced efficacy in controlling tumor growth and prolonging survival in mice, synergizing with immune checkpoint inhibitors.

SourceWyss Institute for Biologically Inspired Engineering at Harvard·JournalNature Nanotechnology·TypeExperimental study·DateMar 15, 2024

Towards a better understanding of endothelial cell transformation in cancer progression

A novel reporter cell experimental system enables the visualization of sequential changes during endothelial-mesenchymal transition (EndoMT) induced by transforming growth factor-β. Researchers identified CD40 as a potential partial EndoMT marker, which suppresses the transition from partial to full EndoMT.

SourceTokyo Medical and Dental University·JournalCancer Science·TypeExperimental study·DateFeb 7, 2024

Team explores role of STING – stimulator of interferon genes – in body’s innate immune system

Researchers provide new insights into STING's function in innate immunity, revealing its role as a scaffold that activates TBK1. They also found that cholesterol plays a crucial role in STING clustering and activation, offering a potential target for treating diseases associated with STING inflammation.

Third-generation anti-CD19 CAR T-cells demonstrate efficacy without neurotoxicity in B-cell lymphoma phase 1 clinical trial

A phase 1 clinical trial demonstrates the efficacy of third-generation anti-CD19 CAR T-cells in treating relapsed or refractory B-cell non-Hodgkin lymphomas without causing neurotoxicity. The study also shows a robust response rate of 52% and improved safety profile compared to previous CAR T-cell therapies.

SourceMalaghan Institute of Medical Research·JournalBlood·TypeExperimental study·DateDec 11, 2023

Breakthrough T cell discovery has huge potential for engineering custom immune responses

Researchers at Institute for Systems Biology have made a breakthrough discovery about T cells, finding that the genetically encoded T-cell receptor sequence determines a T cell's function. This fundamental discovery has huge potential for developing custom immune responses to specific antigens.

SourceInstitute for Systems Biology·JournalCell Reports·TypeRandomized controlled/clinical trial·DateOct 25, 2023

Researchers identify ‘switch’ to activate cancer cell death

A research team from the University of California - Davis Health has identified a crucial epitope on the CD95 receptor that can trigger programmed cell death in cancer cells. This finding could lead to improved cancer treatments and potentially enhance CAR T-cell therapy for solid tumors like ovarian cancer.

SourceUniversity of California - Davis Health·JournalCell Death and Differentiation·TypeExperimental study·DateOct 23, 2023

Cancer-associated fibroblasts: Challenges and opportunities

Cancer-associated fibroblasts (CAFs) are a type of cell that plays a crucial role in the tumor microenvironment. The authors suggest that understanding CAFs is essential for developing effective cancer therapies. Research targeting CAFs has shown promise, but challenges remain due to their complex nature.

SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateApr 5, 2023

International panel led by RCSI Professor classifies immunotherapy side effects for the first time

An international panel of experts has developed standardized definitions for immunotherapy side effects, providing a shared vocabulary for clinicians to standardize clinical practice guidelines. This will help support clinicians in offering the best treatment to patients and enable research into biomarkers predicting adverse effects.

SourceRCSI·JournalJournal for ImmunoTherapy of Cancer·DateApr 4, 2023

Immune system B-cells can help predict HER2-positive breast cancer treatment response

A new study found that measuring activation of immune-system B cells may be better than measuring either T-cell activation or total number of immune cells in and around a tumor. The findings suggest that six signatures of immune cell gene activation from B cells were associated with higher elimination rates and better survival outcomes.

SourceUNC Lineberger Comprehensive Cancer Center·JournalJAMA Oncology·TypeRandomized controlled/clinical trial·DateJan 5, 2023

Cancer patients treated with immunotherapy can safely receive mRNA COVID-19 vaccines, according to JNCCN study

Researchers analyzed 408 patients receiving immune checkpoint inhibitor therapy and found no increased risk of side effects from receiving both immunotherapy and the vaccine. The study supports NCCN's recommendations for COVID-19 vaccination in people with cancer, citing strong protection against severe COVID-19 for all variants.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateOct 17, 2022

Why do men face a higher risk of most types of cancer than women?

A recent study published by Wiley suggests that biological sex differences are the primary reason for higher cancer rates in men compared to women. The study analyzed data from 171,274 males and 122,826 females aged 50-71 years and found that incidence was lower in men only for thyroid and gallbladder cancers.

SourceWiley·JournalCancer·DateAug 8, 2022

Liver cancer’s supercharged metabolism offers a new treatment strategy, Penn study suggests

Researchers discovered that liver cancer cells modify their metabolism to leave them susceptible to disruptions in arginine supply, a key molecule. A three-pronged approach targeting tumor metabolism, blocking survival-promoting responses, and starving tumors of arginine can induce senescence, making cancer cells killable.

SourceUniversity of Pennsylvania School of Medicine·JournalCell Metabolism·TypeExperimental study·DateAug 2, 2022

How fat could help in tailoring cancer treatment plans

A study by Osaka University found that fat accumulation in liver tumors can predict patient response to immunotherapy. The researchers identified a unique tumor immune microenvironment, known as steatotic HCC, which is associated with high infiltration of immune cells but exhaustion of nearby T cells.

SourceOsaka University·JournalHepatology·TypeExperimental study·DateMay 16, 2022

Kiss of sleep: How blood cancer cells put the immune system’s Natural Killer cells to sleep

Researchers have discovered that blood cancer cells steal membranes from immune cells like Natural Killer cells through a process called trogocytosis. This process allows the cancer cells to put the NK cells to sleep, shutting down their anti-cancer activity. The study also sheds light on how PD-1 inhibitors can be used to 'wake up' th...

SourceThe Ottawa Hospital·JournalScience Advances·TypeExperimental study·DateApr 13, 2022